RxDoctor Payments Data

Molham Aldeiri, MD

Cardiovascular Disease · Webster, TXNPI 1356586994

Payments from drug & device makers

$13,972in general payments, 2019–2025

Across 410 payments — averaging $34.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$3K
  • Abiomed$2K
  • Medtronic$1K
  • Edwards Lifesciences$743
  • Merck$409
  • plus $4K from 45 others

What the payments were for

  • Travel & lodging$2,10815%
  • Food & beverage$11,86485%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,972 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$492,135
Medicare patients
605
Services billed
3,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$184,449
XareltoRivaroxaban80$81,166
EntrestoSacubitril/Valsartan21$30,821
FarxigaDapagliflozin Propanediol31$23,901
BrilintaTicagrelor18$14,755
Nebivolol Hcl82$4,243
Metoprolol Succinate164$2,841
Atorvastatin Calcium245$2,327
ClopidogrelClopidogrel Bisulfate191$2,007
Carvedilol201$1,544
Valsartan66$1,333
Losartan Potassium133$1,243
Amlodipine Besylate193$1,071
Flecainide Acetate17$894
Prasugrel Hcl15$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$184,449194 claims
Johnson & JohnsonXarelto$299$81,16680 claims
AstraZenecaFarxiga, Brilinta$87$38,65649 claims
NovartisEntresto$288$30,82121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →